

=====

NPPA COMPLIANCE DOCUMENTATION
BIOPHARMA INDUSTRIES LIMITED

=====

NATIONAL PHARMACEUTICAL PRICING AUTHORITY
(Ministry of Chemicals and Fertilizers, Government of India)

=====

COMPANY REGISTRATION WITH NPPA

=====

REGISTRATION DETAILS:

NPPA Registration Number: NPPA/MH/2013/5678
Company Name: BioPharma Industries Limited
CIN: U24230MH2012PLC234567
Registration Date: June 15, 2013
Status: Active

Registered Office: Plot No. 234-235, MIDC Industrial Area
Thane-Belapur Road, Rabale
Thane - 400701, Maharashtra

Authorized Signatory: Mr. Rajesh Sharma (Chief Financial Officer)
Email: cfo@biopharma.com
Phone: +91-22-2568-XXXX

=====

DRUG PRICE CONTROL ORDER (DPCO) 2013 COMPLIANCE

=====

OVERVIEW:

The Company manufactures pharmaceutical formulations, of which certain products fall under the National List of Essential Medicines (NLEM) and are subject to price control under the Drug Prices Control Order (DPCO), 2013.

PRICE-CONTROLLED PRODUCTS:

Total Products Manufactured: 47
Products under Price Control (NLEM): 18
Non-price-controlled Products: 29

=====

SCHEDULED FORMULATIONS (PRICE-CONTROLLED PRODUCTS)

=====

The following products manufactured by the Company are included in the First Schedule of DPCO, 2013 (National List of Essential Medicines) and are subject to ceiling price:

S.No	Product Name (per unit)	Ceiling Price	MRP	Pack Size
1.	Metformin Hydrochloride 500mg Tablet	Rs. 1.85	Rs. 1.75	Per tablet
2.	Metformin Hydrochloride 850mg Tablet	Rs. 2.12	Rs. 2.00	Per tablet

3. Metformin Hydrochloride 1000mg Tablet	Rs. 2.65	Rs. 2.50 Per tablet
4. Amlodipine Besylate 5mg Tablet	Rs. 1.24	Rs. 1.15 Per tablet
5. Amlodipine Besylate 10mg Tablet	Rs. 1.89	Rs. 1.75 Per tablet
6. Atenolol 50mg Tablet	Rs. 0.82	Rs. 0.75 Per tablet
7. Atenolol 100mg Tablet	Rs. 1.38	Rs. 1.25 Per tablet
8. Losartan Potassium 50mg Tablet	Rs. 3.42	Rs. 3.25 Per tablet
9. Omeprazole 20mg Capsule	Rs. 2.89	Rs. 2.75 Per capsule
10. Pantoprazole 40mg Tablet	Rs. 3.45	Rs. 3.25 Per tablet
11. Ranitidine 150mg Tablet	Rs. 1.12	Rs. 1.00 Per tablet
12. Paracetamol 500mg Tablet	Rs. 0.85	Rs. 0.75 Per tablet
13. Ibuprofen 400mg Tablet	Rs. 1.45	Rs. 1.35 Per tablet
14. Amoxicillin 250mg Capsule	Rs. 3.28	Rs. 3.10 Per capsule
15. Amoxicillin 500mg Capsule	Rs. 5.82	Rs. 5.50 Per capsule
16. Ciprofloxacin 500mg Tablet	Rs. 4.67	Rs. 4.50 Per tablet

17. Albendazole 400mg Tablet Rs. 3.12 Rs. 2.95 Per tablet

18. Ferrous Sulphate + Rs. 1.24 Rs. 1.15 Per tablet
Folic Acid Tablet

PRICING FORMULA (As per DPCO, 2013):

Ceiling Price = (Sum of prices of all brands with >1% market share) /
(Number of such brands)

Ceiling Price is calculated by NPPA based on market data and notified in
official gazette.

RETAIL PRICE FORMULA:

Maximum Retail Price = Ceiling Price + Retailer Margin (16%) + GST

ANNUAL PRICE REVISION:

Prices of scheduled formulations can be increased annually only to the extent
of change in Wholesale Price Index (WPI).

WPI-based Price Increase History:

Year	WPI Increase	Price Revision Applied
2020-21	1.32%	Yes - March 2021
2021-22	3.45%	Yes - April 2022
2022-23	5.67%	Yes - April 2023

2023-24	4.12%	Yes - April 2024
2024-25	3.85%	Yes - April 2025

=====

NON-SCHEDULED FORMULATIONS

=====

For non-price-controlled products, the Company is required to comply with Paragraph 20 of DPCO, 2013:

PRICE INCREASE CAP:

- Maximum price increase allowed: 10% in any 12-month period
- Calculated on manufacturer's MRP (excluding GST)

The Company's non-scheduled products and pricing:

S.No (Current)	Product Name Revision	MRP (%)	Last Price	Increase
1.	Atorvastatin 10mg Tablet	Rs. 8.50	Apr 2024	8.5%
2.	Atorvastatin 20mg Tablet	Rs. 12.00	Apr 2024	8.5%
3.	Rosuvastatin 10mg Tablet	Rs. 15.00	Apr 2024	9.0%
4.	Azithromycin 250mg Tablet	Rs. 28.00	Jul 2025	7.5%
5.	Azithromycin 500mg Tablet	Rs. 45.00	Jul 2025	7.5%
6.	Cefixime 200mg Tablet	Rs. 38.00	Aug 2025	8.0%
7.	Cefpodoxime 200mg Tablet	Rs. 52.00	Apr 2024	9.5%
8.	Pantoprazole 40mg + Domperidone 30mg SR Cap	Rs. 12.50	Sep 2025	N/A (New)
...	(Complete list maintained)			

All price increases are within the 10% annual cap as per DPCO, 2013.

=====

QUARTERLY RETURNS FILED WITH NPPA

=====

As per Para 24 of DPCO, 2013, the Company files quarterly returns with NPPA providing information on:

1. Production quantity of scheduled formulations
2. Stock position
3. Sales quantity and value
4. Interstate stock transfers

RETURN FILING STATUS:

Quarter	Filing Due Date	Filed On	Status
Q1 FY 2024-25	July 15, 2024	July 12, 2024	Timely
Q2 FY 2024-25	Oct 15, 2024	Oct 10, 2024	Timely
Q3 FY 2024-25	Jan 15, 2025	Jan 12, 2025	Timely
Q4 FY 2024-25	Apr 15, 2025	Apr 14, 2025	Timely
Q1 FY 2025-26	July 15, 2025	July 10, 2025	Timely
Q2 FY 2025-26	Oct 15, 2025	Oct 12, 2025	Timely

All returns filed through NPPA's online Integrated Pharmaceutical Database Management System (IPDMS).

=====

ANNUAL RETURNS (FORM V)

=====

As per Para 25 of DPCO, 2013, the Company files Annual Return (Form V) providing audited information on:

1. Total turnover
2. Category-wise sales (scheduled vs non-scheduled)
3. Product-wise production, sales, and closing stock
4. Profit margins

FORM V FILING STATUS:

Financial Year	Filing Due Date	Filed On	Status
FY 2022-23	May 31, 2023	May 28, 2023	Timely
FY 2023-24	May 31, 2024	May 25, 2024	Timely
FY 2024-25	May 31, 2025	May 29, 2025	Timely

=====

TRADE MARGIN RATIONALIZATION

=====

As per NPPA's Trade Margin Rationalization orders, the following products manufactured by the Company have been brought under margin capping:

PRODUCTS UNDER TRADE MARGIN RATIONALIZATION:

These are non-scheduled medicines used in treatment of cancer, diabetes, cardiovascular diseases, etc., where MRP to retailer purchase price ratio exceeds 35%.

Currently, the Company does not manufacture any products falling under Trade Margin Rationalization orders.

=====

OVERCHARGING CASES AND COMPLIANCE

=====

OVERCHARGING STATUS:

The Company has NO overcharging cases pending with NPPA or DPCO enforcement authorities.

COMPLIANCE CERTIFICATE:

This is to certify that BioPharma Industries Limited:

1. Has not charged prices exceeding the ceiling price for any scheduled formulation
2. Has not increased prices of non-scheduled formulations by more than 10% in any 12-month period
3. Has filed all quarterly and annual returns with NPPA within due dates
4. Has maintained proper records of production, sales, and pricing as required under DPCO, 2013
5. Has not received any show cause notice or penalty order from NPPA for overcharging

VERIFICATION:

Period Covered: April 1, 2020 to September 30, 2025
Verified By: M/s. DEF & Co., Chartered Accountants (Statutory Auditors)
Date of Certificate: October 10, 2025

Sd/-
Mr. Rajesh Sharma
Chief Financial Officer

PRICE NOTIFICATIONS AND COMPLIANCE

The Company monitors the following NPPA notifications for price compliance:

- 1. Ceiling Price Notifications (for scheduled formulations)
- 2. WPI-based annual price revision notifications
- 3. Trade margin rationalization orders
- 4. Para 19 price fixation orders
- 5. New additions to NLEM

RECENT PRICE NOTIFICATIONS AFFECTING COMPANY:

Notification No.	Date	Impact on Company
S.O. 2345(E)	Apr 1, 2025	WPI increase 3.85% - Applied
S.O. 1234(E)	Jan 15, 2025	New ceiling for Omeprazole - Complied
S.O. 5678(E)	Oct 10, 2024	New ceiling for Losartan - Complied

PRICE DISPLAY AND LABELING COMPLIANCE

=====

As per DPCO, 2013 and Legal Metrology Act:

1. Maximum Retail Price (MRP) is printed on all product labels
2. MRP is inclusive of all taxes
3. Unit sale price is displayed for scheduled formulations
4. "Price to Retailer" is printed for scheduled formulations
5. Generic name is printed in larger font than brand name

COMPLIANCE STATUS: Fully Compliant

=====

CONTACT INFORMATION FOR NPPA MATTERS

=====

Company Representative:

Name: Mr. Rajesh Sharma
Designation: Chief Financial Officer
Email: cfo@biopharma.com
Phone: +91-22-2568-XXXX
Mobile: +91-98XXX-XXXXX

NPPA Correspondence Address:

National Pharmaceutical Pricing Authority
3rd & 5th Floor, YMCA Cultural Centre Building

1, Jai Singh Road, New Delhi - 110001
Phone: 011-2336-1897
Email: nppa-dop@gov.in
Website: www.nppaindia.nic.in

=====

UNDERTAKING

=====

We, BioPharma Industries Limited, hereby undertake that:

1. We shall comply with all provisions of the Drug Prices Control Order, 2013 and amendments thereto.
2. We shall not charge prices exceeding the ceiling price for scheduled formulations.
3. We shall not increase prices of non-scheduled formulations by more than 10% in any 12-month period without prior approval.
4. We shall file all returns and reports as required under DPCO, 2013.
5. We shall maintain records of production, sales, and pricing for a period of 5 years.
6. We shall cooperate with NPPA authorities for any inspection or verification.
7. In case of any overcharging, we shall deposit the overcharged amount along with interest and penalty as determined by NPPA.

Sd/-

Dr. Ramesh Narayan Kulkarni
Managing Director

Date: November 1, 2025
Place: Thane, Maharashtra

=====
END OF NPPA COMPLIANCE DOCUMENTATION
=====